WO2004052902A1 - Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung - Google Patents
Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung Download PDFInfo
- Publication number
- WO2004052902A1 WO2004052902A1 PCT/EP2003/013454 EP0313454W WO2004052902A1 WO 2004052902 A1 WO2004052902 A1 WO 2004052902A1 EP 0313454 W EP0313454 W EP 0313454W WO 2004052902 A1 WO2004052902 A1 WO 2004052902A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- phenyl
- compounds
- replaced
- Prior art date
Links
- 0 CC(OCC(C(*)(*)C(C1OC(C)=O)OC(C)=O)OC1Br)=O Chemical compound CC(OCC(C(*)(*)C(C1OC(C)=O)OC(C)=O)OC1Br)=O 0.000 description 6
- PLQDWLAHIQPNDV-UHFFFAOYSA-N C=Cc(cc1)ccc1OC1C(OC(C(C2O)O)OC(CO)C2F)=CC=CC1 Chemical compound C=Cc(cc1)ccc1OC1C(OC(C(C2O)O)OC(CO)C2F)=CC=CC1 PLQDWLAHIQPNDV-UHFFFAOYSA-N 0.000 description 1
- WXFFEILSURAFKL-UHFFFAOYSA-N COC(C(C1OC(c2ccccc2)=O)OC(c2ccccc2)=O)OC(COC(c2ccccc2)=O)C1O Chemical compound COC(C(C1OC(c2ccccc2)=O)OC(c2ccccc2)=O)OC(COC(c2ccccc2)=O)C1O WXFFEILSURAFKL-UHFFFAOYSA-N 0.000 description 1
- PKZJLOCLABXVMC-UHFFFAOYSA-N COc1c(C=O)cccc1 Chemical compound COc1c(C=O)cccc1 PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 1
- BKGKCRVOQOWLQA-UHFFFAOYSA-N COc1ccccc1C(c(cc1)ccc1O)=O Chemical compound COc1ccccc1C(c(cc1)ccc1O)=O BKGKCRVOQOWLQA-UHFFFAOYSA-N 0.000 description 1
- PQTAUFTUHHRKSS-UHFFFAOYSA-N Cc1c(Cc2ccccc2)cccc1 Chemical compound Cc1c(Cc2ccccc2)cccc1 PQTAUFTUHHRKSS-UHFFFAOYSA-N 0.000 description 1
- KCOGHZLEAXSUOL-UHFFFAOYSA-N Cc1cc(O)c(C(NCc(cc2)ccc2OC)=O)c(O)c1 Chemical compound Cc1cc(O)c(C(NCc(cc2)ccc2OC)=O)c(O)c1 KCOGHZLEAXSUOL-UHFFFAOYSA-N 0.000 description 1
- KOBFBYNTUGQTTI-UHFFFAOYSA-N OCC(C(C(C1O)O)F)OC1Oc1cc(O)cc(O)c1C(CCc(cc1)ccc1O)=O Chemical compound OCC(C(C(C1O)O)F)OC1Oc1cc(O)cc(O)c1C(CCc(cc1)ccc1O)=O KOBFBYNTUGQTTI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- Novel aromatic fluoroglycoside derivatives medicaments containing these compounds and their use
- the invention relates to substituted aromatic Fluorglycosiddenvate, their physiologically acceptable salts and physiologically functional derivatives.
- Glucopyranosyloxy-pyrazoles from Kissei and Ajinomoto (WO 0268440, WO 0268439, WO 0236602 and WO 0116147) - O-glycoside benzamides from Bristol-Myers Squibb (WO 0174835 and WO 0174834)
- the object of the invention was to provide novel compounds with which a prevention and treatment of diabetes type 1 and type 2 is possible.
- aromatic fluoroglycoside derivatives enhance the effect on SGLT. These compounds are therefore particularly suitable for the prevention and treatment of diabetes type 1 and type 2.
- the invention therefore relates to compounds of the formula I,
- R 3 is OH or F, where at least one of the radicals R 1, R 2, R 3 must be F;
- R 4, R 5, R 6 are hydrogen, F, Cl, Br, J, OH, NO 2 , CN, COOH, CO (CC ⁇ ) -alkyl,
- COO (CC 6) -alkyl, CONH 2, CONH (C 1 -C 6) -alkyl, CON [(C ⁇ -C6) alkyl] 2, (CC 6) alkyl, (C 2 -C 6) - alkenyl, (C 2 -C 6) -alkynyl, (CrC 6) -alkoxy, HO- (CC 6) -
- n is a number from 0 to 4.
- Cyc1 is a 3 to 7-membered saturated, partially saturated or unsaturated
- R 7, R 8, R 9 are hydrogen, F, Cl, Br, J, OH, CF 3 , NO 2 , CN, COOH, COO (CC 6 ) -alkyl, CO (CC 4 ) -alkyl, CONH 2> CONH (-C-) C 6 ) alkyl, CON [(CC 6 ) alkyl] 2, (C
- A is O or NH
- R 4, R 5, R 6 are hydrogen, F, Cl, Br, J, OH, CF 3 , NO 2 , CN, COOH, CO (C 1 -C 6 ) -alkyl, COO (C 1 -C 6 ) -alkyl, CONH 2 , CONH (CC 6 ) -Alkyl, CON [(C 1 -C 6 ) -alkyl] 2 . (d-
- n is a number 0 to 4.
- Cyc1 is a 3 to 7-membered saturated, partially saturated or unsaturated
- R 7, R 8, R 9 are hydrogen, F, Cl, Br, J, OH, CF 3 , NO 2 , CN, COOH, COO (C 1 -C 6 ) -alkyl, CO (C 1 -C 4 ) -alkyl, CONH 2 , CONH (dC 6 ) -alkyl, CON [(dC 6 ) -alkyl] 2, (d-
- C 6 ) alkyl (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (dC 8 ) alkoxy, (C r C 6 ) alkyl OH, (C 1 -C 6 ) -Alkyl-O- (C 1 -C 6 ) -alkyl I SO- (CC 6 ) -alkyl, where in the alkyl radicals one, more, or all hydrogen (s) may be replaced by fluorine; or
- R8 and R9 together with the C atoms carrying them, a 5 to 7-membered, saturated, partially or fully unsaturated ring Cyc2, where 1 or 2 C atom (s) of the ring may also be replaced by N, O or S and Cyc2 optionally by (C 1 -C 6 ) -alkyl, (C 2 -C 5 ) -alkenyl, (C 2 -C 5 ) -alkynyl, where in each case one CH 2 group may be replaced by O, or by H, F, Cl, OH, CF 3 , NO 2 , CN, COO (CC 4 ) alkyl, CONH 2 , CONH (CC) alkyl, OCF 3 may be substituted.
- R 4 , R 5, R 6 are hydrogen, OH, (C 1 -C 6 ) -alkyl, (C 1 -C 4 ) -alkoxy, HO- (CC 4 ) -alkyl, (CC 4 ) -alkyl-O- (C 1 -C 4 ) -alkyl, F, Cl, Br, J, CF 3 , OCF 3 , OCH 2 CF 3 (dC 4 ) - alkyl-CF 2 -, phenyl, benzyl, (C 2 -C 4 ) -alkenyl, (C 2 -C 4 ) -alkynyl , COO (dd) -alkyl;
- n is a number 2 or 3;
- R 7, R 8 , R 9 are hydrogen, (C 1 -C 6 ) -alkyl, (C 1 -C 8 ) -alkoxy, OCF 3 , OCH 2 CF 3 , OH, (C 1 -C 4 ) -alkyl-OH, (C 1 -C 4 ) -alkyl-O - (C 1 -C 4 ) -alkyl, F, Cl, Br or
- R7 is methyl, ethyl, OMe, F, Cl, Br or hydrogen. Very particular preference is also given to compounds of the formula I in which
- R 4 , R 5, R 6 are hydrogen, OH, (CC 4 ) -alkoxy, CF 3 , (C 1 -C 4 ) -alkyl, F, Cl, Br, I,
- n is a number 2 or 3;
- Cyc1 unsaturated 6-membered ring wherein 1 C-atom may be replaced by N or unsaturated 5-membered ring, wherein 1 C-atom may be replaced by S;
- R 7 , R 8, R 9 are hydrogen, OH, (C 1 -C 4 ) -alkyl, (CC 7 ) -alkoxy, OCF 3, halogen or
- R7 is methyl, ethyl, methoxy, F, Cl, Br, hydrogen.
- R 4 is hydrogen, (C 1 -C 4 ) -alkyl, (C 1 -C 4 ) -alkoxy or OH;
- R5 is hydrogen, F, methoxy or ethoxy
- R6 is hydrogen or OH
- B is -CH 2 -, -CO-NH-CH 2 -; -O- or -CO-CH 2 -CH 2 -;
- Cyd is phenyl or thiophene
- R 7, R 8, R 9 are hydrogen, OH, Cl, OCF 3 , (C 1 -C 4 ) -alkyl or (C 1 -C 4 ) -alkoxy; or
- R4 is hydrogen, methyl, methoxy or OH
- R5 is hydrogen, F or methoxy
- R6 is hydrogen or OH
- B is -CH 2 -, -CO-NH-CH 2 -; -O- or -CO-CH 2 -CH 2 -; Cyd phenyl;
- R7 is hydrogen
- R8 is hydrogen, OH, ethyl, Cl, OCF 3 or methoxy
- R9 is hydrogen
- the invention relates to compounds of the formula I, in the form of their racemates, racemic mixtures and pure enantiomers, and to their diastereomers and mixtures thereof.
- alkyl radicals in the substituents R4, R5, R6, R7, R8 and R9 can be both straight-chain and branched.
- halogen is meant F, Cl, Br, J, preferably F and Cl.
- Suitable pharmaceutically acceptable salts are particularly suitable for medical applications because of their higher water solubility compared to the starting or basic compounds. These salts must have a pharmaceutically acceptable anion or cation.
- Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and also organic acids, such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric acid.
- Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth salts (such as magnesium and calcium salts), trometamol (2-amino-2-hydroxymethyl-1, 3-propanediol), diethanolamine, lysine or ethylenediamine.
- Salts with a non-pharmaceutically acceptable anion are also within the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and / or for use in non-therapeutic, for example, in vitro applications.
- physiologically functional derivative refers to any physiologically acceptable derivative of a compound of formula I, e.g. an ester which, when administered to a mammal, e.g. humans, is able to form (directly or indirectly) a compound of formula I or an active metabolite thereof.
- the physiologically functional derivatives also include prodrugs of the compounds according to the invention, as described, for example, in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such prodrugs can be metabolized in vivo to a compound of the invention. These prodrugs may or may not be effective. Preferred are carbonates at the 6-position of the sugar (see WO 0280936 and WO 0244192), more preferably methyl, and ethyl carbonate.
- the compounds according to the invention can also be present in various polymorphic forms, for example as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds of the invention are within the scope of the invention and are a further aspect of the invention.
- references to "compound (s) according to formula I” refer to compound (s) of formula I as described above, as well as their salts, solvates and physiologically functional derivatives as described herein.
- the compound (s) of the formula (I) can also be administered in combination with other active substances.
- the amount of a compound of Formula I required to achieve the desired biological effect is dependent upon a number of factors, e.g. the chosen specific compound, the intended
- the daily dose is in the range of 0.3 mg to 100 mg (typically 3 mg and 50 mg) per day per kilogram of body weight, eg 3-10 mg / kg / day.
- an intravenous dose may range from 0.3 mg to 1.0 mg / kg, which may suitably be administered as an infusion of 10 ng to 100 ng per kilogram per minute.
- Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter.
- Single doses may contain, for example, from 1 mg to 10 g of the active ingredient.
- vials for injections, and orally administrable unit dose formulations may contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg.
- the compounds according to formula I can themselves be used as compound, but they are preferably present with a compatible carrier in the form of a pharmaceutical composition.
- the carrier must of course be compatible in the sense that it is compatible with the other ingredients of the composition and is not harmful to the patient.
- the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a single dose, for example, as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient.
- compositions according to the invention may be prepared according to one of the known Pharmaceutical methods are prepared, which consist essentially in that the ingredients are mixed with pharmacologically acceptable carriers and / or excipients.
- compositions according to the invention are those which are suitable for oral, rectal, topical, peroral (eg sublingual) and parenteral (eg subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration in each individual case is the nature and severity of the treatment State and on the nature of the particular compound used in accordance with formula I is dependent.
- coated formulations and coated slow release formulations are within the scope of the invention. Preference is given to acid and enteric formulations. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
- Suitable pharmaceutical compounds for oral administration may be in separate units, such as capsules, cachets, lozenges or tablets, each containing a certain amount of the compound of formula I; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
- these compositions may be prepared by any suitable pharmaceutical method comprising a step of contacting the active ingredient and the carrier (which may consist of one or more additional ingredients).
- the compositions are prepared by uniformly and homogeneously mixing the active ingredient with a liquid and / or finely divided solid carrier, after which the product is molded, if necessary.
- a tablet can be made by compressing or molding a powder or granules of the compound, optionally with one or more additional ingredients.
- Pressed tablets may be prepared by tableting the compound in free-flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent and / or surfactant / dispersing agent in a suitable machine.
- Molded tablets may be prepared by shaping the powdered compound moistened with an inert liquid diluent in a suitable machine.
- compositions suitable for peroral (sublingual) administration include lozenges containing a compound of formula I with a flavor, usually sucrose and gum arabic or tragacanth, and lozenges containing the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
- Suitable pharmaceutical compositions for parenteral administration preferably comprise sterile aqueous preparations of a compound according to formula I which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also be subcutaneous, intramuscular or intradermal as an injection. These preparations may preferably be prepared by mixing the compound with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions of the invention generally contain from 0.1% to 5% by weight of the active compound.
- Suitable pharmaceutical compositions for rectal administration are preferably as single dose suppositories. These can be prepared by mixing a compound according to formula I with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
- Suitable pharmaceutical compositions for topical application to the skin are preferably as an ointment, cream, lotion, paste, spray, aerosol or oil.
- Vaseline, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances can be used as the carrier.
- the active ingredient is in generally in a concentration of 0.1 to 15% by weight of the composition, for example from 0.5 to 2%.
- Suitable pharmaceutical compositions for transdermal applications may exist as single patches suitable for long-term close contact with the epidermis of the patient. Such patches suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and / or dispersed in an adhesive or dispersed in a polymer.
- a suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%.
- the active ingredient may be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2 (6): 318 (1986).
- the invention furthermore relates to processes for the preparation of the compounds of the general formula I which can be obtained in accordance with the following reaction schemes of the processes A to F:
- the compound (s) of the formula I can also be administered in combination with other active substances.
- active ingredients for the combination preparations are suitable: All antidiabetic medicines mentioned in the Red List 2001, chapter 12. They can be combined with the compounds of the formula I according to the invention in particular for the synergistic effect improvement.
- the administration of the active ingredient combination can be carried out either by separate administration of the active ingredients to the patient or in the form of combination preparations in which several active ingredients are present in a pharmaceutical preparation.
- Most of the drugs listed below are disclosed in USP Dictionary of USAN and International Drug Names, US Pharmacopeia, Rockville 2001.
- Antidiabetics include insulin and insulin derivatives, such as Lantus ® (see www.lantus.com) or HMR 1964 fast-acting insulins (see US 6,221, 633), GLP-1 derivatives such as those described in WO 98/08871 of Novo Nordisk A / S, as well as orally active hypoglycemic agents.
- the orally active hypoglycemic agents preferably include sulphonylureas, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists,
- Potassium channel opener e.g. those disclosed in WO 97/26265 and WO 99/03861 by Novo Nordisk A / S, insulin sensitizers, inhibitors of liver enzymes involved in the stimulation of gluconeogenesis and / or glycogenolysis, modulators of glucose uptake, lipid metabolism altering Compounds such as antihyperlipidemic agents and antilipidemic agents, compounds that reduce food intake, PPAR and PXR agonists, and drugs that act on the ATP-dependent potassium channel of beta cells.
- the compounds of formula I are administered in combination with an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin.
- an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin.
- the compounds of the formula I are administered in combination with a cholesterol absorption inhibitor, such as ezetimibe, tiqueside, pamaqueside.
- a PPAR gamma agonist such as rosiglitazone, pioglitazone, JTT-501, Gl 262570.
- the compounds of formula I in combination with PPAR alpha agonist e.g. GW 9578, GW 7647.
- the compounds of formula I in combination with a mixed PPAR alpha / gamma agonist e.g. GW 1536, AVE 8042, AVE 8134, AVE 0847, AVE0897 or as described in WO 00/64888, WO 00/64876, WO 03/20269.
- a mixed PPAR alpha / gamma agonist e.g. GW 1536, AVE 8042, AVE 8134, AVE 0847, AVE0897 or as described in WO 00/64888, WO 00/64876, WO 03/20269.
- the compounds of formula I are used in combination with a fibrate, e.g. Fenofibrate, clofibrate, bezafibrate.
- a fibrate e.g. Fenofibrate, clofibrate, bezafibrate.
- the compounds of formula I are administered in combination with an MTP inhibitor, e.g. Implitapide, BMS-201038, R-103757.
- an MTP inhibitor e.g. Implitapide, BMS-201038, R-103757.
- the compounds of formula I are used in combination with bile acid resorption inhibitor (see, e.g., U.S. 6,245,744 or U.S. 6,221,897), e.g. HMR 1741 administered.
- the compounds of formula I are administered in combination with a CETP inhibitor, e.g. JTT-705.
- a CETP inhibitor e.g. JTT-705.
- the compounds of formula I are administered in combination with a polymeric bile acid adsorbent such as cholestyramine, colesevelam.
- a polymeric bile acid adsorbent such as cholestyramine, colesevelam.
- the compounds of formula I are administered in combination with an LDL receptor inducer (see US 6,342,512), such as HMR1171, HMR1586.
- the compounds of formula I are administered in combination with an ACAT inhibitor, e.g. Avasimibe, administered.
- an ACAT inhibitor e.g. Avasimibe
- the compounds of formula I are used in combination with an antioxidant, e.g. OPC-14117 administered.
- the compounds of formula I are used in combination with a lipoprotein lipase inhibitor, e.g. NO-1886, administered.
- a lipoprotein lipase inhibitor e.g. NO-1886
- the compounds of formula I are used in combination with an ATP citrate lyase inhibitor, e.g. SB-204990 administered.
- the compounds of formula I are administered in combination with a squalene synthetase inhibitor, e.g. BMS-188494.
- a squalene synthetase inhibitor e.g. BMS-188494.
- the compounds of formula I in combination with a lipoprotein (a) antagonist, e.g. CI-1027 or nicotinic acid.
- a lipoprotein (a) antagonist e.g. CI-1027 or nicotinic acid.
- the compounds of formula I are administered in combination with a lipase inhibitor, e.g. Orlistat, administered.
- a lipase inhibitor e.g. Orlistat
- the compounds of the formula I are administered in combination with insulin.
- the compounds of formula I are administered in combination with a sulphonylurea, such as, for example, tolbutamide, glibenclamide, glipizide or glimepiride.
- the compounds of formula I are administered in combination with a biguanide such as metformin.
- the compounds of formula I are used in combination with a meglitinide, e.g. Repaglinide, administered.
- the compounds of formula I are used in combination with a thiazolidinedione, e.g. Troglitazone, ciglitazone, pioglitazone, rosiglitazone or those described in WO 97/41097 by Dr. med. Reddy's Research Foundation disclosed compounds, particularly 5 - [[4 - [(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy) phenyl] methyl] -2,4-thiazolidinedione.
- the compounds of formula I are used in combination with a ⁇ -glucosidase inhibitor, e.g. Miglitol or acarbose, administered.
- a ⁇ -glucosidase inhibitor e.g. Miglitol or acarbose
- the compounds of formula I are administered in combination with an agent which acts on the ATP-dependent potassium channel of the beta cells, e.g. Tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
- the compounds of formula I are used in combination with more than one of the aforementioned compounds, e.g. in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
- the compounds of the formula I are used in combination with CART modulators (see “Cocaine-amphetamine-regulated transcript-influenced energy metabolism, anxiety and gastric emptying in mice” Asakawa, A, et al., M.: Hormones and Metabolism Research (2001), 33 (9), 554-558), NPY antagonists eg naphthalene-1-sulfonic acid ⁇ 4 - [(4-amino-quinazolin-2-ylamino) -methyl] -cyclohexylmethyl ⁇ -amide; hydrochloride (CGP 71683A)), MC4 agonists (eg, 1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid [2- (3a-benzyl-2-methyl-3-oxo-2,3 , 3a, 4,6,7-hexahydro-pyrazolo [4,3-c] pyridin-5-yl) -1- (4-ch
- 5HT agonists e.g. 1- (3-ethylbenzofuran-7-yl) -piperazine oxalic acid salt (WO 01/09111), bombesin agonists, galanin antagonists, growth hormone (eg, human growth hormone), growth hormone releasing compounds (6-benzyloxy-1- (2 -diisopropylamino-ethylcarbamoyl) -3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (WO 01/85695)), TRH agonists (see, eg, EP 0 462
- decoupling protein 2- or 3-modulators decoupling protein 2- or 3-modulators, leptin agonists (see, eg, Lee, Daniel W., Leinung, Matthew C; Rozhavskaya-Arena, Marina; Grasso, Patricia.) Leptin agonists as a potential approach to the treatment of obesity of the Future (2001), 26 (9), 873-881), DA agonists (bromocriptine, doprexin), lipase / amylase inhibitors (eg WO
- PPAR modulators e.g., WO 00/78312
- RXR modulators e.g., TR-yff agonists.
- the further active ingredient is leptin; see, e.g. "Perspectives in the therapeutic use of leptin", Salvador, Javier; Gomez- 25 Ambrosi, Javier; Fruhbeck, Ge, Expert Opinion on Pharmacotherapy (2001), 2 (10), 1615-1622.
- the further active ingredient is dexamphatamine or amphetamine.
- the other active ingredient is fenfluramine or dexfenfluramine.
- the other active ingredient is sibutramine.
- the other active ingredient is orlistat.
- the other active ingredient is mazindol or phentermine.
- the compounds of formula I in combination with bulking agents preferably insoluble bulking agents
- bulking agents preferably insoluble bulking agents
- Caromax is a carob-containing product of the company Nutrinova, Nutrition Specialties & Food Ingredients GmbH, Industriepark availability, 65926 Frankfurt / Main)) administered.
- Combination with Caromax ® is possible in one preparation or by separate administration of compounds of the formula I and Caromax ®.
- Caromax ® can also be administered in the form of food, such as in baked goods or muesli bars.
- MS is ok means that a mass spectrum or HPLC / MS was measured and in which the molecular peak +1 (MH + ) and / or M + 18 (MNH 4 + ) and / or M + 23 ( MNa + ) was detected.
- the compounds of the formula I are distinguished by favorable effects on the glucose metabolism, in particular they lower the blood sugar level and are suitable for the treatment of type 1 and type 2 diabetes.
- the compounds can therefore be used alone or in combination with other blood sugar-lowering agents (antidiabetics).
- the compounds of the formula I are furthermore suitable for the prevention and treatment of diabetic late damage, such as e.g. Nephropathy, retinopathy, neuropathy, syndrome X, obesity, myocardial infarction, myocardial infarction, peripheral arterial occlusive diseases, thrombosis, arteriosclerosis, inflammation, immune diseases, autoimmune diseases, e.g. AIDS, asthma, osteoporosis, cancer, psoriasis, Alzheimer's disease, schizophrenia and infectious diseases, preferred are the treatment of type 1 and type 2 diabetes as well as for the prevention and treatment of diabetic late damage, syndrome X and obesity.
- diabetic late damage such as e.g. Nephropathy, retinopathy, neuropathy, syndrome X, obesity, myocardial infarction, myocardial infarction, peripheral arterial occlusive diseases, thrombosis, arteriosclerosis, inflammation, immune diseases, autoimmune diseases, e.g. AIDS, asthma, osteoporosis, cancer, psori
- the preparation of brush border membrane vesicles from the intestinal cells of the small intestine was carried out by the so-called Mg 2+ precipitation method.
- the mucosa from the small intestine was scraped off and suspended in 60 ml of ice-cold Tris / HCl buffer (pH 7.1) / 300 mM mannitol, 5 mM EGTA. After dilution to 300 ml with ice-cold distilled water was with an Ultraturrax (18-rod, IKA plant Staufen, Germany) 2 x 1 minute at 75% max. Power homogenized with ice cooling.
- the precipitate is taken up in 30 ml of 20 mM Tris / Hepes buffer (pH 7.4) / 280 mM mannitol and homogeneously resuspended by 20 strokes in a Potter Elveihem homogenizer at 1000 rpm. After 30 minutes of centrifugation at 48,000 xg (20,000 rpm, SS-34 rotor), the precipitate was dissolved in 0.5 to 2 ml Tris / Hepes buffer (pH 7.4) / 280 mM mannitol (final concentration 20 mg / ml). ml) and resuspended using a tuberculin syringe with a 27 gauge needle. The vesicles were either used immediately after preparation for labeling or transport studies or were stored at -160 ° C. in 4 mg portions in liquid nitrogen.
- rabbits were sacrificed by intravenous injection of 0.5 ml of an aqueous solution of 2.5 mg tetracaine HCl, 100 mg of m-butramide and 25 mg of mezoconium iodide.
- the small intestines were removed, rinsed with ice cold physiological saline and frozen in plastic bags under nitrogen at -80 ° C and stored for 4 to 12 weeks.
- the frozen intestines were added to prepare the membrane vesicles Thawed at 30 ° C in a water bath and then scraped off the mucosa. Working up to membrane vesicles was carried out as described above.
- the brush border membrane vesicles were prepared from the cortex of the rat kidney by the method of Biber et al.
- the kidneys of 6 to 8 rats (200 to 250 g) were removed and of each kidney, the cortex was about 1 mm thick
- the kidneys were taken up in 30 ml of ice-cold 12 mM Tris / HCl buffer (pH 7.4) / 300 mM Mannitol and homogenized with ice cooling for 4 ⁇ 30 seconds using an Ultraturrax rod (180 V stage). After adding 42 ml of ice-cold distilled water, 850 ⁇ l of a 1M MgCl 2 solution was added. After 15 minutes incubation at 0 ° C, 15 minutes at 4 500 rpm (Sorvall SS-34 rotor)
- the transport process was stopped by the addition of 1 ml ice-cold stop solution (10 mM Tris / Hepes buffer (pH 7.4) / 150 mM KCl) and the vesicle suspension was immediately passed through a membrane filter at a vacuum of 25 to 35 mbar Cellulose nitrate (0.45 microns, 25 mm diameter, Schleicher & Schull) aspirated. The filter was rinsed with 5 ml ice-cold stop solution. Each measuring point was carried out as a double or triple determination.
- the membrane filter was dissolved in 4 ml of a suitable scintillator (Quickszint 361, Zinsser Analytik GmbH, Frankfurt am Main) and the radioactivity was determined by liquid-ice scintillation measurement. The measured values were obtained after calibration of the device with the help of standard samples and after correction of any existing chemiluminescence as dpm (disintegrations per minute).
- a suitable scintillator Quickszint 361, Zinsser Analytik GmbH, Frankfurt am Main
- the activity comparison of the drugs is performed on IC 50 data obtained in the rabbit small intestinal brush border membrane vesicle transport assay for selected substances. (The absolute values may be species- and experiment-dependent) Example No. IC50 [ ⁇ M]
- oxidation can be done with Jones reagent:
- 2,61g (4-methoxy-phenyl) - (2-methoxyphenyl) -methanone 52 are dissolved in dichloromethane.
- the batch is cooled in an ice bath and 3.71 g of boron tribromide-dimethyl sulfide complex are added.
- the mixture is warmed to room temperature and allowed to stir for 3 h.
- the reaction is stopped by pouring into ice water, the dichloromethane phase is separated and the aqueous phase is extracted several times with ethyl acetate.
- the combined organic phase is washed with water and sodium chloride solution, dried over sodium sulfate and concentrated.
- Example 20 The following examples are prepared in an analogous manner as Example 20 using the 5 corresponding aglycones:
- the corresponding aglycones can be obtained, for example, by the methods described for compound 7 or 10 56.
- Example 24 20 230 mg of Compound 72 are reacted with sodium methoxide analogously to the release of Example 20.
- the connection can be through Kieselelchromatographie (dichloromethane: methanol 96: 4) are purified. 119 mg of the desired product are obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0316605-8A BR0316605A (pt) | 2002-12-12 | 2003-11-28 | Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação |
AU2003298149A AU2003298149B2 (en) | 2002-12-12 | 2003-11-28 | Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof |
EP03795853A EP1572707B1 (de) | 2002-12-12 | 2003-11-28 | Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
SI200330239T SI1572707T1 (sl) | 2002-12-12 | 2003-11-28 | Novi aromatski fluorglikozidni derivati, farmacevtski proizvodi, ki vsebujejo te spojine, in njihova uporaba |
MXPA05005825A MXPA05005825A (es) | 2002-12-12 | 2003-11-28 | Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que contienen estos compuestos y su uso. |
DE50302843T DE50302843D1 (de) | 2002-12-12 | 2003-11-28 | Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CA2508024A CA2508024C (en) | 2002-12-12 | 2003-11-28 | Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof |
NZ540694A NZ540694A (en) | 2002-12-12 | 2003-11-28 | Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof |
KR1020057010711A KR101059705B1 (ko) | 2002-12-12 | 2003-11-28 | 신규한 방향족 플루오로글리코사이드 유도체 및 당해 화합물을 포함하는 약제학적 제품 |
YUP-2005/0394A RS50775B (sr) | 2002-12-12 | 2003-11-28 | Novi aromatični derivati fluorglikozida, lekovi koji sadrže ova jedinjenja i njihova primena |
JP2004557952A JP4806192B2 (ja) | 2002-12-12 | 2003-11-28 | 新しい芳香族フルオログリコシド誘導体、該化合物を含有する医薬品、およびその使用 |
IL168924A IL168924A (en) | 2002-12-12 | 2005-06-01 | Aromatic fluoroglycoside derivatives, pharmaceutical products containing these compounds and their use |
HRP20050531AA HRP20050531B1 (hr) | 2002-12-12 | 2005-06-10 | Novi aromatski derivati fluorglikozida, lijek koji sadrži te spojeve i njihova upotreba |
NO20053212A NO330376B1 (no) | 2002-12-12 | 2005-06-30 | Aromatiske fluorglukosidderivater, anvendelse derav, legemiddel inneholdende en eller flere slike forbindelser samt fremgangsmate for fremstilling av dette |
HK06104255A HK1084124A1 (en) | 2002-12-12 | 2006-04-07 | Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof |
CY20061100810T CY1105617T1 (el) | 2002-12-12 | 2006-06-07 | Νεα αρωματικα παραγωγα των φθορογλυκοσιδων, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10258007.3 | 2002-12-12 | ||
DE10258007A DE10258007B4 (de) | 2002-12-12 | 2002-12-12 | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004052902A1 true WO2004052902A1 (de) | 2004-06-24 |
Family
ID=32477574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/013454 WO2004052902A1 (de) | 2002-12-12 | 2003-11-28 | Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
Country Status (36)
Country | Link |
---|---|
US (2) | US7288528B2 (de) |
EP (1) | EP1572707B1 (de) |
JP (1) | JP4806192B2 (de) |
KR (1) | KR101059705B1 (de) |
CN (1) | CN100368420C (de) |
AR (1) | AR042438A1 (de) |
AT (1) | ATE321769T1 (de) |
AU (1) | AU2003298149B2 (de) |
BR (1) | BR0316605A (de) |
CA (1) | CA2508024C (de) |
CY (1) | CY1105617T1 (de) |
DE (2) | DE10258007B4 (de) |
DK (1) | DK1572707T3 (de) |
ES (1) | ES2259777T3 (de) |
GT (1) | GT200300269A (de) |
HK (1) | HK1084124A1 (de) |
HN (1) | HN2003000407A (de) |
HR (1) | HRP20050531B1 (de) |
IL (1) | IL168924A (de) |
JO (1) | JO2354B1 (de) |
MA (1) | MA27559A1 (de) |
MX (1) | MXPA05005825A (de) |
MY (1) | MY139303A (de) |
NO (1) | NO330376B1 (de) |
PA (1) | PA8592201A1 (de) |
PE (1) | PE20040909A1 (de) |
PL (1) | PL210848B1 (de) |
PT (1) | PT1572707E (de) |
RS (1) | RS50775B (de) |
RU (1) | RU2340622C2 (de) |
SI (1) | SI1572707T1 (de) |
SV (1) | SV2004001691A (de) |
TW (1) | TWI320043B (de) |
UY (1) | UY28123A1 (de) |
WO (1) | WO2004052902A1 (de) |
ZA (1) | ZA200503364B (de) |
Cited By (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004075815A2 (de) | 2003-02-27 | 2004-09-10 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2006058597A1 (de) * | 2004-12-03 | 2006-06-08 | Merck Patent Gmbh | Tetrahydropyranderivate als antidiabetika |
JP2006232825A (ja) * | 2005-01-31 | 2006-09-07 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO2006131231A1 (de) | 2005-06-09 | 2006-12-14 | Sanofi-Aventis | Azolopyridin-2-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2007128761A2 (de) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Verwendungen von dpp iv inhibitoren |
WO2007147478A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3 -amino- imidazo [1, 2-a] pyridinderivate als sglt inhibitoren |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
JP2008508213A (ja) * | 2004-07-27 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法 |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
US7419959B2 (en) | 2004-10-01 | 2008-09-02 | Boehringer Ingelheim International, Gmbh | D-pyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
EP2048150A1 (de) * | 2006-08-04 | 2009-04-15 | Daiichi Sankyo Company, Limited | Benzylphenylglucopyranosid-derivat |
DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
WO2009100936A2 (de) * | 2008-02-13 | 2009-08-20 | Sanofi-Aventis | Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US7579449B2 (en) | 2004-03-16 | 2009-08-25 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
US7662790B2 (en) | 2005-04-15 | 2010-02-16 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7683160B2 (en) | 2005-08-30 | 2010-03-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7713938B2 (en) | 2005-05-03 | 2010-05-11 | Boehringer Ingelheim International Gmbh | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2010066643A1 (de) * | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Verfahren zur herstellung von 4-fluoro-4-desoxy-alpha-d-glucopyranoside |
US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US7767651B2 (en) | 2005-01-28 | 2010-08-03 | Chugai Seiyaku Kabushiki Kaisha | Spiroketal derivatives and use thereof as diabetic medicine |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US7772378B2 (en) | 2005-02-23 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7776830B2 (en) | 2006-05-03 | 2010-08-17 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US7847074B2 (en) | 2005-09-15 | 2010-12-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof |
US7851617B2 (en) | 2006-07-27 | 2010-12-14 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
US7851602B2 (en) | 2005-07-27 | 2010-12-14 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
WO2011039338A2 (en) | 2009-10-02 | 2011-04-07 | Sanofi-Aventis | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
US7935674B2 (en) | 2005-01-31 | 2011-05-03 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
US7943582B2 (en) | 2006-12-04 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
US7943788B2 (en) | 2003-08-01 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8048897B2 (en) | 2004-07-26 | 2011-11-01 | Chugai Seiyaku Kabushiki Kaisha | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8507450B2 (en) | 2005-09-08 | 2013-08-13 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
US8551957B2 (en) | 2007-08-16 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
US8772512B2 (en) | 2009-07-10 | 2014-07-08 | Janssen Pharmaceutica Nv | Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene |
WO2014108350A1 (en) | 2013-01-14 | 2014-07-17 | Basf Se | Method of fracturing subterranean formations |
US8802842B2 (en) | 2009-09-30 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form |
US8853385B2 (en) | 2008-01-17 | 2014-10-07 | Mitsubishi Tanabe Pharma Corporation | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors |
US9024010B2 (en) | 2009-09-30 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US9024009B2 (en) | 2007-09-10 | 2015-05-05 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US9174971B2 (en) | 2009-10-14 | 2015-11-03 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EP3330341A1 (de) | 2016-12-01 | 2018-06-06 | Basf Se | Verfahren zur unterirdischen formationsbrechung |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10544135B2 (en) | 2011-04-13 | 2020-01-28 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US10617668B2 (en) | 2010-05-11 | 2020-04-14 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
US11207337B2 (en) | 2015-09-15 | 2021-12-28 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
US11576894B2 (en) | 2009-07-08 | 2023-02-14 | Janssen Pharmaceutica Nv | Combination therapy for the treatment of diabetes |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
US7803778B2 (en) * | 2006-05-23 | 2010-09-28 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
US20080027014A1 (en) * | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
ES2397664T3 (es) * | 2006-12-04 | 2013-03-08 | Janssen Pharmaceutica, N.V. | Derivados de glucopiranósilo que contienen tienilo como antidiabéticos |
US7795228B2 (en) * | 2006-12-28 | 2010-09-14 | Theracos, Inc. | Spiroheterocyclic glycosides and methods of use |
WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
EP2064222B1 (de) * | 2007-04-02 | 2014-05-07 | Theracos, Inc. | Benzylische glycosidderivate und verfahren zu ihrer verwendung |
JP5272395B2 (ja) * | 2007-12-12 | 2013-08-28 | セントラル硝子株式会社 | 4−デオキシ−4−フルオロ−d−グルコース誘導体の製造方法 |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
HUE029970T2 (en) | 2008-08-22 | 2017-04-28 | Theracos Sub Llc | Method for producing SGLT2 inhibitors |
RS52236B (en) * | 2008-08-28 | 2012-10-31 | Pfizer Inc. | DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA |
EP2342187A1 (de) * | 2008-09-19 | 2011-07-13 | Novartis AG | Glykosidderivate und anwendungen davon |
WO2010077623A1 (en) | 2008-12-08 | 2010-07-08 | Sanofi-Aventis | Intermediates and processes for the preparation of fluoroglycoside derivatives |
ES2527179T3 (es) | 2009-11-02 | 2015-01-21 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
WO2011060256A2 (en) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
PL2498759T3 (pl) | 2009-11-13 | 2019-03-29 | Astrazeneca Ab | Formulacje tabletek o natychmiastowym uwalnianiu |
RU2564901C2 (ru) | 2009-11-13 | 2015-10-10 | Бристол-Майерс Сквибб Кампани | Композиции метформина с уменьшенной массой |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
CN103338767B (zh) | 2010-08-04 | 2018-06-22 | 弗吉尼亚大学专利基金会 | 治疗炎症性疾病的组合物和方法 |
EP2611442B1 (de) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Wirkstoffformulierungen mit waserlöslichen antioxidanzien |
US9181292B2 (en) * | 2011-01-05 | 2015-11-10 | Pi-Hui Liang | Methods for preparation of glycosphingolipids and uses thereof |
JP2014504639A (ja) | 2011-02-01 | 2014-02-24 | ブリストル−マイヤーズ スクイブ カンパニー | アミン化合物を含む医薬製剤 |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
CN104610208B (zh) * | 2013-11-05 | 2017-08-15 | 天津药物研究院有限公司 | (1s)‑1,6‑二脱氧‑1‑[4‑甲氧基‑3‑(反式‑4‑正丙基环己基)甲基苯基]‑d‑吡喃葡萄糖的晶型a及其制备方法和应用 |
WO2019215633A1 (en) | 2018-05-09 | 2019-11-14 | Janssen Pharmaceutica Nv | 5,5-difluoro- and 5-fluoro-5-methyl-c-glycoside derivatives useful as dual sglt1 / sglt2 modulators |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0850948A1 (de) * | 1996-12-26 | 1998-07-01 | Tanabe Seiyaku Co., Ltd. | Propiophenonderivate und Verfahren zu ihrer Herstellung |
WO2001027128A1 (en) * | 1999-10-12 | 2001-04-19 | Bristol-Myers Squibb Company | C-aryl glucoside sglt2 inhibitors |
EP1213296A1 (de) * | 1999-08-31 | 2002-06-12 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US6068834A (en) | 1994-03-04 | 2000-05-30 | The Procter & Gamble Company | Skin lightening compositions |
HUP9902056A3 (en) | 1996-01-17 | 2002-02-28 | Novo Nordisk As | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
EP0910351A1 (de) | 1996-06-27 | 1999-04-28 | G.D. Searle & Co. | Amphiphile copolymere umfassende teilchen mit einem quervernetzten hüll- und einem inneren kernbereich, verwendbar für pharmazeutische und andere anwendungen |
JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
JP3055135B2 (ja) * | 1996-12-26 | 2000-06-26 | 田辺製薬株式会社 | プロピオフェノン誘導体及びその製法 |
PT958296E (pt) | 1996-12-31 | 2003-11-28 | Reddys Lab Ltd Dr | Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas |
EP0953357A1 (de) | 1997-01-17 | 1999-11-03 | Drug Delivery System Institute, Ltd. | Nephotropische Arzneien |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
WO1999003861A1 (en) | 1997-07-16 | 1999-01-28 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
US6545117B1 (en) * | 1997-08-07 | 2003-04-08 | Akzo Noble N.V. | Sprayable coating compositions comprising an oxazolidine functional compound, an isocyanate functional compound, and a compound selected from a mercapto and a sulfonic acid functional compound |
CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
JP2000080041A (ja) * | 1998-03-09 | 2000-03-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
JP2002542245A (ja) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 置換イミダゾール、それらの製造および使用 |
JP4598278B2 (ja) | 1999-04-28 | 2010-12-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ppar受容体リガンドとしてのジアリール酸誘導体 |
SK15522001A3 (sk) | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
CA2371271A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
EP1194146B1 (de) | 1999-06-18 | 2006-07-19 | Merck & Co., Inc. | Arylthiazolidinedione und aryloxa zolidinedion-derivate |
AU768310B2 (en) | 1999-07-29 | 2003-12-04 | Eli Lilly And Company | Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
AU774071B2 (en) | 1999-09-01 | 2004-06-17 | Sanofi-Aventis Deutschland Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
AU4114601A (en) * | 2000-03-17 | 2001-09-24 | Kissei Pharmaceutical | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
ATE369337T1 (de) | 2000-04-28 | 2007-08-15 | Asahi Kasei Pharma Corp | Neue bizyklische verbindungen |
CA2408486A1 (en) | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
WO2001091752A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
EP1294704A1 (de) | 2000-06-29 | 2003-03-26 | Abbott Laboratories | Aryl-phenylheterocyclyl-sulfid-derivate und deren anwendung als zelladhäsionshemmende anti-inflammatorische und immunsuppressive mittel |
SK287811B6 (sk) * | 2000-09-29 | 2011-10-04 | Kissei Pharmaceutical Co., Ltd | Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu |
DE60141156D1 (de) * | 2000-11-02 | 2010-03-11 | Ajinomoto Kk | Neue pyrazolderivate und diese enthaltende mittel gegen diabetes |
US7053060B2 (en) * | 2000-11-30 | 2006-05-30 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
DE60230591D1 (de) * | 2001-02-26 | 2009-02-12 | Kissei Pharmaceutical | Glykopyranosyloxypyrazolderivate und deren medizinische verwendung |
CA2438595C (en) * | 2001-02-27 | 2011-08-09 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
US6838442B2 (en) * | 2001-04-04 | 2005-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators |
JP4590159B2 (ja) * | 2001-04-04 | 2010-12-01 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | グルコース再吸収阻害剤およびpparモジュレーターを含んで成る併用療法 |
US6884812B2 (en) | 2001-08-31 | 2005-04-26 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals |
ATE347890T1 (de) | 2001-08-31 | 2007-01-15 | Sanofi Aventis Deutschland | Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren |
-
2002
- 2002-12-12 DE DE10258007A patent/DE10258007B4/de not_active Expired - Fee Related
-
2003
- 2003-11-28 KR KR1020057010711A patent/KR101059705B1/ko not_active IP Right Cessation
- 2003-11-28 WO PCT/EP2003/013454 patent/WO2004052902A1/de active IP Right Grant
- 2003-11-28 RS YUP-2005/0394A patent/RS50775B/sr unknown
- 2003-11-28 DK DK03795853T patent/DK1572707T3/da active
- 2003-11-28 PL PL375789A patent/PL210848B1/pl unknown
- 2003-11-28 EP EP03795853A patent/EP1572707B1/de not_active Expired - Lifetime
- 2003-11-28 BR BR0316605-8A patent/BR0316605A/pt not_active IP Right Cessation
- 2003-11-28 AU AU2003298149A patent/AU2003298149B2/en not_active Ceased
- 2003-11-28 MX MXPA05005825A patent/MXPA05005825A/es active IP Right Grant
- 2003-11-28 PT PT03795853T patent/PT1572707E/pt unknown
- 2003-11-28 ES ES03795853T patent/ES2259777T3/es not_active Expired - Lifetime
- 2003-11-28 CN CNB2003801057115A patent/CN100368420C/zh not_active Expired - Fee Related
- 2003-11-28 JP JP2004557952A patent/JP4806192B2/ja not_active Expired - Fee Related
- 2003-11-28 CA CA2508024A patent/CA2508024C/en not_active Expired - Fee Related
- 2003-11-28 AT AT03795853T patent/ATE321769T1/de active
- 2003-11-28 SI SI200330239T patent/SI1572707T1/sl unknown
- 2003-11-28 RU RU2005121905/04A patent/RU2340622C2/ru not_active IP Right Cessation
- 2003-11-28 DE DE50302843T patent/DE50302843D1/de not_active Expired - Lifetime
- 2003-12-03 GT GT200300269A patent/GT200300269A/es unknown
- 2003-12-09 JO JO2003164A patent/JO2354B1/en active
- 2003-12-10 HN HN2003000407A patent/HN2003000407A/es unknown
- 2003-12-10 PE PE2003001250A patent/PE20040909A1/es not_active Application Discontinuation
- 2003-12-10 TW TW092134767A patent/TWI320043B/zh not_active IP Right Cessation
- 2003-12-11 AR ARP030104575A patent/AR042438A1/es unknown
- 2003-12-11 MY MYPI20034746A patent/MY139303A/en unknown
- 2003-12-12 UY UY28123A patent/UY28123A1/es unknown
- 2003-12-12 US US10/735,179 patent/US7288528B2/en not_active Expired - Lifetime
- 2003-12-12 SV SV2003001691A patent/SV2004001691A/es not_active Application Discontinuation
- 2003-12-12 PA PA20038592201A patent/PA8592201A1/es unknown
-
2005
- 2005-04-26 ZA ZA200503364A patent/ZA200503364B/en unknown
- 2005-06-01 IL IL168924A patent/IL168924A/en not_active IP Right Cessation
- 2005-06-10 HR HRP20050531AA patent/HRP20050531B1/hr not_active IP Right Cessation
- 2005-06-10 MA MA28326A patent/MA27559A1/fr unknown
- 2005-06-30 NO NO20053212A patent/NO330376B1/no not_active IP Right Cessation
-
2006
- 2006-04-07 HK HK06104255A patent/HK1084124A1/xx not_active IP Right Cessation
- 2006-06-07 CY CY20061100810T patent/CY1105617T1/el unknown
-
2007
- 2007-10-29 US US11/926,697 patent/US20080108580A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0850948A1 (de) * | 1996-12-26 | 1998-07-01 | Tanabe Seiyaku Co., Ltd. | Propiophenonderivate und Verfahren zu ihrer Herstellung |
EP1213296A1 (de) * | 1999-08-31 | 2002-06-12 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung |
WO2001027128A1 (en) * | 1999-10-12 | 2001-04-19 | Bristol-Myers Squibb Company | C-aryl glucoside sglt2 inhibitors |
Non-Patent Citations (1)
Title |
---|
WITHERS, S.G. ET AL.: "2-Deoxy-2-fluoroglucosides: a novel class of mechanism-based glucosidase inhibitors", J. AM. CHEM. SOC., vol. 109, 1987, pages 7530 - 1, XP002275265 * |
Cited By (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004075815A2 (de) | 2003-02-27 | 2004-09-10 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US7943788B2 (en) | 2003-08-01 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
US8202984B2 (en) | 2003-08-01 | 2012-06-19 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
EP2360164A2 (de) | 2004-03-16 | 2011-08-24 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
EP2360165A2 (de) | 2004-03-16 | 2011-08-24 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US7579449B2 (en) | 2004-03-16 | 2009-08-25 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
EP2295422A2 (de) | 2004-03-16 | 2011-03-16 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
US8048897B2 (en) | 2004-07-26 | 2011-11-01 | Chugai Seiyaku Kabushiki Kaisha | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes |
JP2008508213A (ja) * | 2004-07-27 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法 |
US7419959B2 (en) | 2004-10-01 | 2008-09-02 | Boehringer Ingelheim International, Gmbh | D-pyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2006058597A1 (de) * | 2004-12-03 | 2006-06-08 | Merck Patent Gmbh | Tetrahydropyranderivate als antidiabetika |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7767651B2 (en) | 2005-01-28 | 2010-08-03 | Chugai Seiyaku Kabushiki Kaisha | Spiroketal derivatives and use thereof as diabetic medicine |
US7935674B2 (en) | 2005-01-31 | 2011-05-03 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
JP2006232825A (ja) * | 2005-01-31 | 2006-09-07 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US7772378B2 (en) | 2005-02-23 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7662790B2 (en) | 2005-04-15 | 2010-02-16 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7713938B2 (en) | 2005-05-03 | 2010-05-11 | Boehringer Ingelheim International Gmbh | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US10442795B2 (en) | 2005-05-10 | 2019-10-15 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US9127034B2 (en) | 2005-05-10 | 2015-09-08 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivates and intermediates therein |
WO2006131231A1 (de) | 2005-06-09 | 2006-12-14 | Sanofi-Aventis | Azolopyridin-2-on-derivate als inhibitoren von lipasen und phospholipasen |
US7851602B2 (en) | 2005-07-27 | 2010-12-14 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7683160B2 (en) | 2005-08-30 | 2010-03-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US8507450B2 (en) | 2005-09-08 | 2013-08-13 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
US7847074B2 (en) | 2005-09-15 | 2010-12-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof |
US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US7776830B2 (en) | 2006-05-03 | 2010-08-17 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US8557782B2 (en) | 2006-05-03 | 2013-10-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
WO2007128761A2 (de) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Verwendungen von dpp iv inhibitoren |
EP2351568A2 (de) | 2006-05-04 | 2011-08-03 | Boehringer Ingelheim International GmbH | Verwendungen von dpp iv Inhibitoren |
WO2007147478A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3 -amino- imidazo [1, 2-a] pyridinderivate als sglt inhibitoren |
US7851617B2 (en) | 2006-07-27 | 2010-12-14 | Mitsubishi Tanabe Pharma Corporation | Indole derivatives |
EP2048150A1 (de) * | 2006-08-04 | 2009-04-15 | Daiichi Sankyo Company, Limited | Benzylphenylglucopyranosid-derivat |
EP2048150A4 (de) * | 2006-08-04 | 2011-06-29 | Daiichi Sankyo Co Ltd | Benzylphenylglucopyranosid-derivat |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7943582B2 (en) | 2006-12-04 | 2011-05-17 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
US8513202B2 (en) | 2006-12-04 | 2013-08-20 | Mitsubishi Tanabe Pharma Corporation | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US8551957B2 (en) | 2007-08-16 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
US9024009B2 (en) | 2007-09-10 | 2015-05-05 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
WO2009049731A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo [ 1, 2 -a] pyrimidinderivate zur behandlung von erkrankungen wie diabetes |
US8853385B2 (en) | 2008-01-17 | 2014-10-07 | Mitsubishi Tanabe Pharma Corporation | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors |
WO2009100936A2 (de) * | 2008-02-13 | 2009-08-20 | Sanofi-Aventis | Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2009100936A3 (de) * | 2008-02-13 | 2009-10-22 | Sanofi-Aventis | Neue aromatische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
WO2009124638A1 (de) | 2008-04-07 | 2009-10-15 | Merck Patent Gmbh | Glucopyranosidderivate |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2010066643A1 (de) * | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Verfahren zur herstellung von 4-fluoro-4-desoxy-alpha-d-glucopyranoside |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11576894B2 (en) | 2009-07-08 | 2023-02-14 | Janssen Pharmaceutica Nv | Combination therapy for the treatment of diabetes |
US8772512B2 (en) | 2009-07-10 | 2014-07-08 | Janssen Pharmaceutica Nv | Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
US9873714B2 (en) | 2009-09-30 | 2018-01-23 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US9024010B2 (en) | 2009-09-30 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US8802842B2 (en) | 2009-09-30 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form |
WO2011039338A2 (en) | 2009-10-02 | 2011-04-07 | Sanofi-Aventis | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US9174971B2 (en) | 2009-10-14 | 2015-11-03 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US8828951B2 (en) | 2009-10-20 | 2014-09-09 | Novartis Ag | Glycoside derivatives and uses thereof |
US8466114B2 (en) | 2009-10-20 | 2013-06-18 | Novartis Ag | Glycoside derivatives and uses thereof |
USRE49080E1 (en) | 2009-10-20 | 2022-05-24 | Novartis Ag | Glycoside derivatives and uses thereof |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
US9895389B2 (en) | 2009-10-20 | 2018-02-20 | Novartis Ag | Glycoside derivatives and uses thereof |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US10617668B2 (en) | 2010-05-11 | 2020-04-14 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US11564886B2 (en) | 2011-03-07 | 2023-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10596120B2 (en) | 2011-03-07 | 2020-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US10544135B2 (en) | 2011-04-13 | 2020-01-28 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2014108350A1 (en) | 2013-01-14 | 2014-07-17 | Basf Se | Method of fracturing subterranean formations |
US9701891B2 (en) | 2013-01-14 | 2017-07-11 | Basf Se | Method of fracturing a subterranean formation with use flowback aids |
US10258637B2 (en) | 2013-04-05 | 2019-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11090323B2 (en) | 2013-04-05 | 2021-08-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11833166B2 (en) | 2013-04-05 | 2023-12-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11918596B2 (en) | 2013-04-05 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11207337B2 (en) | 2015-09-15 | 2021-12-28 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
EP3330341A1 (de) | 2016-12-01 | 2018-06-06 | Basf Se | Verfahren zur unterirdischen formationsbrechung |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1572707B1 (de) | Neue aromatische fluorglycosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung | |
EP1572708B1 (de) | Neue heterocyclische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung | |
DE10231370B4 (de) | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel | |
EP1758914B1 (de) | Neue fluorglykosidderivate von pyrazolen, diese verbindungen enthaltende arzneimittel und deren verwendung | |
EP1862455B1 (de) | 11-((4R,6R)-4,5,6-Trihydroxy-3-(R)-hydroxy-2-(S)-hydroxy-hexylcarbamoyl)-Undekansäure | |
WO2007009655A1 (de) | 1,4-BENZOTHIAZEPIN-l, 1-DIOXIDDERIVAT, VERFAHREN ZU DESSEN HERSTELLUNG, DIESE VERBINDUNG ENTHALTENDE ARZNEIMITTEL UND DESSEN VERWENDUNG ALS HYPOLIPIDÄMIKUM | |
EP1713804A1 (de) | Cycloalkyl substituierte 7-amino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
DE10246434B4 (de) | Carboxyalkoxy-substituierte Acyl-carboxyphenyl-harnstoffderivate und ihre Verwendung als Arzneimittel | |
DE102004004973A1 (de) | 7-Phenylamino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-2005/0394 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500781 Country of ref document: PH Ref document number: 200503364 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003795853 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2508024 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/005825 Country of ref document: MX Ref document number: 168924 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003298149 Country of ref document: AU Ref document number: 05056018 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 375789 Country of ref document: PL Ref document number: 1020057010711 Country of ref document: KR Ref document number: 20038A57115 Country of ref document: CN Ref document number: 540694 Country of ref document: NZ Ref document number: 2004557952 Country of ref document: JP Ref document number: P20050531A Country of ref document: HR Ref document number: 1183/CHENP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005121905 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057010711 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003795853 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0316605 Country of ref document: BR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003795853 Country of ref document: EP |